Gaurav Patel, MD
Interventional Cardiology · Tyler, TXNPI 1376922476
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,128 of the $4,262 with a category attached, or 73.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2022 at $1,501 and has fallen 91.4% since, to $129 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 72 payments — averaging $59.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$917
- Edwards Lifesciences$509
- Boston Scientific$331
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$326
- E.r. Squibb & Sons, L.L.C.$243
- Actelion Pharmaceuticals US, Inc.$240
- plus $2K from 17 others
Across 13 payments — averaging $1789.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$23K
What the payments were for
- Travel & lodging$52912%
- Food & beverage$3,12873%
- Education$53112%
- Gifts$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $917 |
| Edwards Lifesciences | 6 | $509 |
| Boston Scientific | 4 | $331 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $326 |
| E.r. Squibb & Sons, L.L.C. | 3 | $243 |
| Actelion Pharmaceuticals US, Inc. | 9 | $240 |
| Abbott | 1 | $227 |
| Pfizer | 7 | $215 |
| Chiesi USA, Inc. | 2 | $207 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Eisai Inc. | 1 | $112 |
| Esperion Therapeutics, Inc. | 1 | $102 |
| Inari Medical, Inc. | 1 | $99 |
| Astellas Pharma US Inc | 1 | $99 |
| Abiomed | 1 | $99 |
| Novartis | 5 | $96 |
| Shockwave Medical, Inc | 1 | $82 |
| ZOLL Circulation Inc | 1 | $76 |
| Harmony Biosciences LLC | 3 | $59 |
| Cvrx, Inc. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| AstraZeneca | 1 | $23 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,262 in reported general payments places this provider in the 20th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $204,572 |
| BrilintaTicagrelor | 40 | $31,458 |
| XareltoRivaroxaban | 22 | $23,387 |
| EntrestoSacubitril/Valsartan | 12 | $20,568 |
| Rosuvastatin Calcium | 135 | $2,385 |
| Midodrine Hcl | 21 | $2,203 |
| Atorvastatin Calcium | 227 | $2,112 |
| Metoprolol Succinate | 110 | $1,360 |
| Isosorbide Dinitrate | 15 | $1,296 |
| Ranolazine ErRanolazine | 20 | $1,171 |
| ClopidogrelClopidogrel Bisulfate | 114 | $1,035 |
| Torsemide | 34 | $952 |
| Amlodipine Besylate | 118 | $857 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 38 | $819 |
| Metoprolol Tartrate | 110 | $756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $204,572170 claims |
| AstraZenecaBrilinta | $23 | $31,45840 claims |
| NovartisEntresto | $96 | $20,56812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Tyler
- Jeffrey CarrTyler$1.9M
- Preetham Reddy MuskulaTyler$91K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.